Should Continuous Infusion 5-Fluorouracil Become the Standard of Care in the USA as It Is in Europe?
Authors:
- Anthony B. El-KhoueiryAEAnthony B. El-Khoueiry
- Heinz-Josef LenzHLHeinz-Josef Lenz
- 1 January 2006
- journal article
- review article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 24 (1) , 50-55
Abstract
The mechanism of action of 5-fluorouracil (5-FU) and its pharmacologic behavior are influenced by its mode of administration. Several clinical studies have been conducted with the purpose of evaluating the difference between the continuous (CI 5-FU) and the bolus infusion of 5-FU (BI 5-FU). We focus our review on the studies relevant to the treatment of colorectal cancer, both in the adjuvant and metastatic setting. While individual trials fail to show a survival benefit for CI 5-FU, a meta-analyses of 7 trials shows an improvement in overall survival (OS) over BI 5-FU in metastatic colorectal cancer treatment. All trials in the same setting reveal a different toxicity profile for CI 5-FU that is generally more favorable than BI 5-FU. In the adjuvant setting, CI 5-FU allows the duration of therapy to be shortened by half without compromising the efficacy. CI 5-FU is the regimen of choice when given concurrently with radiation. When given in combination with other cytotoxic agents, CI 5-FU seems to be associated with less toxicity and potentially higher efficacy. Oral fluoropyrimidines, especially capecitabine, appear to behave in similar manner to CI 5-FU and may offer a convenient alternative to the usage of infusion pumps and indwelling catheters. While clinical trials are ongoing to compare capecitabine to CI 5-FU, we believe that CI 5-FU should be offered to patients in the United States given its favorable toxicity profile and higher efficacy in several settings.Keywords
This publication has 33 references indexed in Scilit:
- Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: An Updated Meta-AnalysisJournal of Clinical Oncology, 2004
- Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation TherapyJournal of Clinical Oncology, 2004
- XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004
- Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952Journal of Clinical Oncology, 2003
- Phase III Study of Bolus Versus Infusion Fluorouracil With or Without Cisplatin in Advanced Colorectal CancerJNCI: Journal of the National Cancer Institute, 1996
- Heterogeneity of 5-fluorouracil radiosensitivity modulation in cultured mammalian cell linesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1992
- 5-Fluorouracil by Protracted Venous Infusion: A Review of Recent Clinical StudiesCancer Investigation, 1991
- 5-Fluorouracil by Protracted Venous InfusionOncology, 1989
- The incorporation of 5-fluoro-2′-deoxyuridine into DNA of mammalian tumor cellsBiochemical and Biophysical Research Communications, 1981